Page last updated: 2024-11-08

3-(hydroxyacetyl)indole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(hydroxyacetyl)indole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID200631
CHEMBL ID524903
CHEBI ID173472
SCHEMBL ID4056357
MeSH IDM0499650

Synonyms (38)

Synonym
HMS1482H11
OPREA1_735053
AKOS005431093
2400-51-3
hydroxymethyl indol-3-yl ketone
CHEBI:173472
IDI1_021243
ethanone, 2-hydroxy-1-(1h-indol-3-yl)-
2-hydroxy-1-(1h-indol-3-yl)ethanone
brn 0142060
3-glyceroindole
CHEMDIV3_003333
STK386423
INDOLE-3-KETOL ,
2-hydroxy-1-(indol-3-yl)ethanone
smr000386954
MLS001049127
3-(hydroxylacetyl)-indole
CHEMBL524903
3-(hydroxyacetyl)indole
NCGC00182562-01
2-hydroxy-1-(1h-indol-3-yl)-ethanone
IBLZDDPFMAFWKP-UHFFFAOYSA-N
SCHEMBL4056357
cambridge id 5106709
DTXSID80178731
2-hydroxy-1-(1h-indol-3-yl)ethan-1-one
mfcd00466496
hydroxymethyl indol-3-yl ketone, 8ci
2-hydroxy-1-(1h-indol-3-yl)ethanone, 9ci
3-hydroxyacetylindole
SY131003
2-hydroxy-1-(3-indolyl)ethanone
AC5698
3-(hydroxyacetyl)-indole
BS-36792
CS-0450037
CAA40051
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
L-tryptophan degradation V (side chain pathway)020

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1370495Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Chemical constituents from Taraxacum officinale and their α-glucosidase inhibitory activities.
AID376958Growth inhibition of human DU145 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID376957Growth inhibition of human KM20L2 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID376955Growth inhibition of human SF268 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID1370496Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate at 200 uM preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Chemical constituents from Taraxacum officinale and their α-glucosidase inhibitory activities.
AID376952Growth inhibition of mouse P388 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID376953Growth inhibition of human BXPC3 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID376956Growth inhibition of human NCI-H460 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID376954Growth inhibition of human MCF7 cells2006Journal of natural products, May, Volume: 69, Issue:5
Antineoplastic Agents. 554. The manitoba bacterium Streptomyces sp.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's8 (66.67)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.99 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]